-
Mashup Score: 0Zoledronic Acid for Prevention of Bone Loss in Patients Receiving Primary Therapy for Lymphomas: A Prospective, Randomized Controlled Phase III Trial - 2 month(s) ago
Micro-AbstractIn patients with newly diagnosed lymphoma, low bone mineral density (BMD) is common at diagnosis and worsens with therapy. Our randomized phase III trial demonstrates that 2 doses of zoledronic acid (ZA) and supplementation with calcium and vitamin D effectively prevent further bone loss.
Categories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 30
Patients with multiple myeloma (MM) may be on therapy for years, which can lead to financial toxicity (FinTox) or time toxicity (TimeTox). The prevalence, predictors, and quality of life (QOL) impacts of FinTox and TimeTox during different phases of MM treatment have not been characterized.
Categories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 4Dampening Logistics Creating Inequitable Access- A Major Threat Despite Advancements - 3 month(s) ago
We read with great interest the recent publication by Shahzad et al. titled “Geographic and Racial Disparities in Chimeric Antigen Receptor–T Cells and Bi-specific Antibodies Trials Access for Diffuse Large B-Cell Lymphoma” which is a report on the distribution across the US of chimeric antigen receptor T cell (CART) and bispecific therapies1. Shahzad et al. demonstrated that the 126 studies were distributed over 31 states, however, there is considerable variation by region in the availability of the trial.
Categories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0Rates of Influenza and Pneumococcal Vaccination and Correlation With Survival in Multiple Myeloma Patients - 3 month(s) ago
MicroabstractWe analyzed vaccination rates and associated outcomes of patients with multiple myelom in the INSIGHT MM study. Influenza vaccination in the prior 2 years and pneumococcal vaccination in the prior 5 years impacted overall survival versus no vaccination. Additionally, deaths due to infections were lower among vaccinated versus non-vaccinated patients. Vaccination status should be recorded in prospective clinical trials as it may affect survival.
Categories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1Vaccination in Multiple Myeloma: Review of Current Literature - 3 month(s) ago
Multiple myeloma is a cancer of the immune system. Infection is a major cause of morbidity and mortality in patients with multiple myeloma. Some of these infections are preventable by vaccines available to the general population. However, little is known about the clinical effectiveness of these vaccines in patients with multiple myeloma, and the cellular and humoral immune response to vaccination has not been well characterized, especially in conjunction with modern myeloma therapies. The present report reviews the basics of multiple myeloma and the immune system, the available evidence on the immunologic response of patients with multiple myeloma after vaccination, and current practice recommendations regarding specific vaccines.
Categories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 8
Chimeric Antigen Receptor T-cell (CAR T-cell) therapy is an effective treatment for relapsed/refractory (R/R) large B cell lymphoma (LBCL). However, patients with central nervous system (CNS) lymphoma were excluded in most of the CAR T-cell therapy trials. This meta-analysis assesses the efficacy with CAR T-cell therapy in LBCL patients with CNS involvement. Two reviewers independently searched PubMed and Cochrane Library to identify all published literature associated with United States Food and Drug Administration approved CAR T-cell therapies for LBCL.
Categories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 51Recent Advances in the Biology and CD123-Directed Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm - 3 month(s) ago
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a clinically aggressive hematologic malignancy1-3 with an overall incidence of approximately 500 to 1000 cases per year in the US and a greater prevalence in those aged 60 years or older. However, the true incidence of BPDCN is likely higher than these numbers indicate, as there may be substantial under-reporting. The median age of patients with BPDCN is 65 to 70 years.4-6 Men are affected at a roughly 3-to-1 ratio to women.1-3,6-9 Pediatric cases represent approximately 10% of total cases and are reportedly less severe, with greater potential for long-lasting remission or cure.
Categories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 106
The combination of low-intensity chemotherapy and inotuzumab ozogamicin (INO), with sequential blinatumomab, is highly effective in older adults with newly diagnosed B-cell acute lymphoblastic leukemia (ALL) and in relapsed or refractory B-cell ALL. Earlier, “dose-dense” administration of blinatumomab could lead to earlier and deeper measurable residual disease (MRD) responses and better outcomes.
Categories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0Rates of Influenza and Pneumococcal Vaccination and Correlation With Survival in Multiple Myeloma Patients - 5 month(s) ago
MicroabstractWe analyzed vaccination rates and associated outcomes of patients with multiple myelom in the INSIGHT MM study. Influenza vaccination in the prior 2 years and pneumococcal vaccination in the prior 5 years impacted overall survival versus no vaccination. Additionally, deaths due to infections were lower among vaccinated versus non-vaccinated patients. Vaccination status should be recorded in prospective clinical trials as it may affect survival.
Categories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0Rates of Influenza and Pneumococcal Vaccination and Correlation With Survival in Multiple Myeloma Patients - 5 month(s) ago
MicroabstractWe analyzed vaccination rates and associated outcomes of patients with multiple myelom in the INSIGHT MM study. Influenza vaccination in the prior 2 years and pneumococcal vaccination in the prior 5 years impacted overall survival versus no vaccination. Additionally, deaths due to infections were lower among vaccinated versus non-vaccinated patients. Vaccination status should be recorded in prospective clinical trials as it may affect survival.
Categories: General Medicine News, Hem/OncsTweet
Zoledronic Acid for Prevention of Bone Loss in Lymphoma [12/29/12] @Lymphoma_Doc @mtmdphd et al. CLML https://t.co/iPOYSXEA1M #lymsm #SuppOnc #BoneHealth - Clinical Practice Points: 1) Incr risk low BMD in ND & incr risk on Tx, 2) 2 doses ZA stabilize BMD, 3) Screening